ocrelizumab/hyaluronidase

{{Short description|Combination medication}}

{{Use American English|date=September 2024}}

{{Use dmy dates|date=September 2024}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| type = combo

| image =

| width =

| alt =

| caption =

| component1 = Ocrelizumab

| class1 = Monoclonal antibody

| component2 = Hyaluronidase

| class2 = Endoglycosidase

| tradename = Ocrevus Zunovo

| Drugs.com = {{drugs.com|parent|Ocrevus-zunovo}}

| MedlinePlus =

| DailyMedID = Ocrelizumab and hyaluronidase

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Subcutaneous

| ATC_prefix = None

| ATC_suffix =

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Ocrevus Zunovo- ocrelizumab and hyaluronidase injection, solution | website=DailyMed | date=25 September 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b216af61-99d0-42a3-afc2-b5bf86df1ec0 | access-date=5 October 2024}}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| synonyms =

}}

Ocrelizumab/hyaluronidase, sold under the brand name Ocrevus Zunovo, is a fixed-dose combination medication used for the treatment of multiple sclerosis. It contains ocrelizumab, a recombinant humanized monoclonal antibody directed at CD20; and hyaluronidase (human recombinant), an endoglycosidase. It is taken by subcutaneous injection.

Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.{{cite press release | title=FDA Approves Ocrevus Zunovo as the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis | website=Genentech | date=13 September 2024 | url=https://www.gene.com/media/press-releases/15036/2024-09-13/fda-approves-ocrevus-zunovo-as-the-first | access-date=13 September 2024 | archive-date=14 September 2024 | archive-url=https://web.archive.org/web/20240914061044/https://www.gene.com/media/press-releases/15036/2024-09-13/fda-approves-ocrevus-zunovo-as-the-first | url-status=live }}{{cite press release | title=Halozyme Announces FDA Approval of Roche's Subcutaneous Ocrevus Zunovo with Enhanze for People with Relapsing and Primary Progressive Multiple Sclerosis | publisher=Halozyme Therapeutics | via=PR Newswire | date=13 September 2024 | url=https://www.prnewswire.com/news-releases/halozyme-announces-fda-approval-of-roches-subcutaneous-ocrevus-zunovo-with-enhanze-for-people-with-relapsing-and-primary-progressive-multiple-sclerosis-302247928.html | access-date=13 September 2024 | archive-date=14 September 2024 | archive-url=https://web.archive.org/web/20240914061013/https://www.prnewswire.com/news-releases/halozyme-announces-fda-approval-of-roches-subcutaneous-ocrevus-zunovo-with-enhanze-for-people-with-relapsing-and-primary-progressive-multiple-sclerosis-302247928.html | url-status=live }}